In 2004, the Dutch parliament enacted the Wet donorgegevens kunstmatige bevruchting — the Act on Donor Data for Artificial Insemination, known by its initials WDKB. It was a significant moment in European reproductive medicine ethics: for the first time, the right of a donor-conceived child to know their biological origins was enshrined in law. Anonymity for new donors was prohibited. Children could, from the age of sixteen, request the identifying information of their biological donor.
The response from the medical community was predictable. Clinics warned that sperm and egg donors would disappear. Some did — temporarily. In the first years after the WDKB came into force, donor numbers fell. Then something unexpected happened: a new cohort emerged, drawn not by financial compensation (which had always been modest in the Netherlands) but by a different motivation entirely. These were people who found meaning in helping others become parents, and who had no objection to the possibility of future contact with the children they had helped create.
Twenty years on, the Netherlands demonstrates that open donation and a functional donor pool are not contradictory. The country is not a high-volume reproductive tourism destination — it is not competing with Spain or the Czech Republic on price. What it offers instead is legal clarity, ethical coherence, a decades-long infrastructure for open-identity donation, and a society that was the first in the world to legalise same-sex marriage (2001).
The Netherlands has one of the more comprehensive ART frameworks in Europe, shaped by a tradition of progressive social legislation and a strong emphasis on individual rights.
The Netherlands legalised same-sex marriage in 2001 — the first country in the world to do so. ART access for female same-sex couples followed naturally from this legal architecture. For a married lesbian couple using donor sperm, both women are automatically registered as legal mothers at birth — no adoption, no court process, no separate legal co-parenting agreement required. The presumption of parenthood is built into the system.
For single women, access to ART is generally available, though some Dutch clinics require a psychological assessment. For heterosexual couples with medical indication, treatment is covered by the national insurance up to age 43.
The practical architecture of open donation in the Netherlands is unusually well-developed, largely because of the central role of Fiom — an independent specialist organisation whose mandate goes far beyond data storage.
Under the WDKB, every donor registering at a Dutch clinic must consent to the potential disclosure of their data. The system creates a tiered access structure based on the child's age:
From age 12: the child may request non-identifying information — the donor's medical history and physical description. This allows children (and their parents) to answer practical health questions without yet having full identifying information.
From age 16: the child may request the donor's full identifying information — name, date of birth, last known contact address. Requests are processed through Fiom, which manages the national donor registry and provides psychological counselling throughout the process.
Crucially, disclosure under the WDKB does not trigger any legal relationship. The donor does not acquire parental rights, financial obligations, or any claim on the child. The intended parents remain the sole legal parents. This separation — genetic information without legal parentage — is what makes the Dutch open donation model functional in practice.
The fear that open donation would collapse donor supply rested on a specific assumption: that donors were primarily motivated by financial gain, and that removing anonymity would remove their willingness to donate. This assumption turned out to be partially correct in the short run — and largely wrong in the medium run.
The sperm donor pool did temporarily decline in 2004–2007. Some established anonymous donors stopped registering. New donors were slower to emerge. The transitional period was genuinely difficult for some Dutch clinics, and some patients sought donor sperm abroad.
But by 2010, the trend had reversed. Dutch academic studies of donor motivations found that the post-WDKB cohort was substantially different in profile from the pre-WDKB cohort. The new donors were more likely to be motivated by a genuine desire to help others build families, and less likely to be motivated by financial compensation. This produced a paradox: the system that looked more demanding on paper produced a more stable and more committed donor base in practice.
The United Kingdom experienced a nearly identical trajectory when it ended donor anonymity in 2005. Initially, numbers fell. Over time, they recovered and exceeded pre-reform levels. The systematic fear — that open donation would make donation impossible — was not borne out in either country.
The Netherlands' position as the world's first country to legalise same-sex marriage is not merely symbolic — it means that the legal architecture for recognising same-sex families predates the ART access questions. The result is an unusually clean and well-tested framework.
For a married lesbian couple using donor sperm, both women are legal mothers from birth by operation of law. No additional legal steps are required. The same applies to civil partnerships.
For an unmarried lesbian couple, the non-birth mother must formally acknowledge the child within a defined period after birth. The process is standard and well-understood; fertility clinics provide documentation guidance as part of their patient pathway.
For single women, access to ART is available in the Netherlands, though not uniformly so. Some Dutch clinics apply an additional psychological assessment, and some have waiting lists that are somewhat longer for single patients than for couples. In practice, most single women who wish to receive ART in the Netherlands are able to access it — though the process may require more persistence than in, for example, Spain or Belgium.
For individuals considering co-parenting — where two people not in a romantic relationship intend to raise a child together — the Dutch legal framework presents specific practical considerations. The Netherlands has a well-developed family law tradition but does not yet have a single statute specifically governing co-parenting as a distinct family structure.
In practice, co-parenting arrangements in the Netherlands are typically governed by a combination of elements:
A co-parenting agreement drawn up by a Dutch notary or family law attorney, setting out the intended arrangements for care, financial responsibility, and decision-making. This document is not a formal legal registration but provides a framework that can be enforced through Dutch civil law.
A formal acknowledgement of parenthood for the non-birth parent (if they are not the biological parent and not married to the birth parent), which may require a court process depending on the configuration.
The Netherlands is not the cheapest European destination for fertility treatment. It is not competing on price. Patients come for legal clarity, donor identity transparency, and high clinical standards — not for cost savings relative to Eastern European destinations.
| Treatment | Typical price (EUR) |
|---|---|
| Own IVF cycle (full) | 3,000–5,500 |
| Donor egg cycle (full) | 5,000–8,000 |
| Donor sperm per cycle | 800–1,500 |
| PGT-A add-on | +1,500–3,000 |
| FET (frozen embryo transfer) | 900–1,800 |
Zorgverzekering (national health insurance) covers part of IVF costs for women under 43 with a recognised medical indication, at an accredited Dutch centre. Reimbursement typically covers a limited number of cycles and requires a referral from a general practitioner. Foreign patients are treated privately and pay the full tariff.
Prices in the Netherlands are comparable to Germany and Switzerland, and significantly above Czech Republic, Spain, or Poland. For patients from countries where reproductive tourism is necessary due to legal restrictions at home, the Dutch price point is not the first consideration — legal framework and donor identity access are.
The Netherlands has a modest number of licensed fertility centres relative to its population — a feature, not a limitation. The Dutch Health and Youth Care Inspectorate (IGJ) applies rigorous licensing standards. All fertility centres must maintain and publish IVF outcome statistics, including live birth rates by age group. The regulatory environment is demanding, and clinical standards are uniformly high.
Major Dutch fertility centres include:
Amsterdam UMC — One of the most research-active centres in Europe, with particular strength in fertility preservation, PGT, and male factor treatment. Two campuses (AMC and VUmc), both operating under the UMC umbrella.
Radboud University Medical Centre (Nijmegen) — A leading academic centre with recognised expertise in genetic counselling, carrier screening, and complex family-building configurations including single women and same-sex couples.
Erasmus MC Rotterdam — High volume, comprehensive services including complex donor cases and fertility preservation for oncology patients.
UMCG Groningen — Serving the northern Netherlands and patients arriving from nearby Germany and Scandinavia. Research focus includes preterm birth, endometriosis, and embryo development.
Dutch medical research on cumulative live birth rates, embryo selection, and long-term child outcomes has contributed significantly to international ART guidelines.
By volume, the Netherlands is not in the same league as Spain, Czech Republic, or Belgium as a reproductive tourism destination. Dutch fertility clinics are not structured to process large numbers of international patients through high-throughput protocols. They are primarily designed to serve the Dutch population and operate within a regulatory framework that does not incentivise rapid international expansion.
However, for specific patient groups, the Netherlands offers something that volume-focused destinations cannot provide: a fully mature open-identity donation infrastructure, decades of legal evolution around same-sex families, a well-funded psychological support system (Fiom), and a legal framework that has resolved most of the ambiguity around donor-conceived children's rights.
The Netherlands is not the right choice for everyone. Waiting times can be longer than in Belgium or Spain. Prices are higher than Eastern European destinations. The clinic network is not optimised for international patient flow. But for patients whose primary concerns are transparency, legal coherence, and their future child's right to know their origins, it is in a category of its own.